Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2002
06/20/2002WO2002048165A2 Antiviral agents for treatment of flaviviridae infections
06/20/2002WO2002048149A1 NOVEL ss-LACTAM COMPOUNDS AND PROCESS FOR PREPARING THE SAME
06/20/2002WO2002048148A2 Pyrazolopyridine derivatives
06/20/2002WO2002048147A2 Pyrazolopyridines
06/20/2002WO2002048143A2 Antimicrobial 2-pyridones, their compositions and uses
06/20/2002WO2002048139A2 Oxazolidinone photoaffinity probes
06/20/2002WO2002048138A1 Antimicrobial quinolones
06/20/2002WO2002048117A1 Quinazolinone derivatives
06/20/2002WO2002048114A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents
06/20/2002WO2002047730A2 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
06/20/2002WO2002047727A1 Therapeutic agent comprising a b-subunit of a protein toxin
06/20/2002WO2002047720A2 Treatment and prevention of ebv infection and ebv-associated disorders
06/20/2002WO2002047718A2 Methods and compositions for vaccination comprising nucleic acid ad/or polypeptide sequences of $i(chlamydia)
06/20/2002WO2002047708A2 Selective cox-2 inhibition from edible plant extracts
06/20/2002WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
06/20/2002WO2002047700A1 Composite & making method of medicines for cold treatment
06/20/2002WO2002047698A1 Remedies for dermatophytosis
06/20/2002WO2002047695A1 Blocking the adsorption of germs in birds
06/20/2002WO2002047681A1 Regulation of bacterial virulence
06/20/2002WO2002047615A2 Oral compositions and use thereof
06/20/2002WO2002047474A1 Transgenic animal expressing hla-a24 and utilization thereof
06/20/2002WO2002040518A8 Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant
06/20/2002WO2002031110A3 Hematopoietic stem cell gene therapy
06/20/2002WO2002030888A3 Tricyclic compounds and uses thereof
06/20/2002WO2002030320A3 Stimulation of thymus for vaccination development
06/20/2002WO2002022567A8 Novel thio derivatives of sordarin as antifungal agents
06/20/2002WO2002022077A3 Compositions and methods for inhibition of hiv-1 infection
06/20/2002WO2002016436A3 ANTIBODIES TO HUMAN IL-1$g(b)
06/20/2002WO2002016312A3 NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
06/20/2002WO2002008393A3 Serine protease from yersinia enterocolitica
06/20/2002WO2002008226A3 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors
06/20/2002WO2002007763A3 Helicobacter pylori with modified lipopolysaccharide biosynthesis
06/20/2002WO2002006190A3 Crystalline and salt forms of an hiv protease inhibitor
06/20/2002WO2002004422A3 Heterocycle carboxamides as antiviral agents
06/20/2002WO2002003910A3 Antibacterial, antioxidant, immunomoduling and anticancerogenic preparation and method for using said preparation
06/20/2002WO2002000208A3 Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
06/20/2002WO2002000165A3 Agent for reversal of drug resistance in mycobacterium tuberculosis
06/20/2002WO2001098518A3 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes
06/20/2002WO2001095933A3 Immunization through oral administration of a vaccine with an edible product
06/20/2002WO2001085959A3 Regulation of human lysostaphin-like protease
06/20/2002WO2001085942A3 Cytoskeleton-associated proteins
06/20/2002WO2001083524A3 Rna metabolism proteins
06/20/2002WO2001077113A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
06/20/2002WO2001064755A3 Isoxazole gegen virale erkrankungen
06/20/2002WO2001054771A3 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
06/20/2002WO2001053487A3 Human sperm specific lysozyme-like proteins
06/20/2002WO2001044445A8 Human lyases and associated proteins
06/20/2002WO2001014576A8 Process and intermediates for the preparation of isoxazolecaroxamides and analogues
06/20/2002WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
06/20/2002WO2000067734A3 Use of phthalazine derivatives
06/20/2002WO2000061596A8 50 human secreted proteins
06/20/2002WO2000052185A9 Application of dna vectors for the treatment of viral infection
06/20/2002US20020077506 For therapy of inflammatory or painful disorder
06/20/2002US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis
06/20/2002US20020077460 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
06/20/2002US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition
06/20/2002US20020077351 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation
06/20/2002US20020077343 H2 receptor antagonist compounds in combination with nitric oxide donors, compostions and methods of use
06/20/2002US20020077339 Chemokine receptor binding heterocyclic compounds
06/20/2002US20020077338 HIV protease inhibitors
06/20/2002US20020077337 Chemical compounds
06/20/2002US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2)
06/20/2002US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis
06/20/2002US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder
06/20/2002US20020077304 Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
06/20/2002US20020077298 Anti-fungal peptides
06/20/2002US20020077280 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
06/20/2002US20020077271 Compounds and methods of use to treat infectious diseases
06/20/2002US20020076796 2786, a novel human aminopeptidase
06/20/2002US20020076793 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4
06/20/2002US20020076789 Method for treating herpes viruses
06/20/2002US20020076766 Novel glucosaminidase
06/20/2002US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain
06/20/2002US20020076446 Novel medicinal herbal composition for treating liver diseases and HIV
06/20/2002US20020076430 Micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate; and a water soluble cellulose compound; foaming, freezing and freeze-drying
06/20/2002US20020076418 Use of strains of parapoxvirus ovis against organ fibrosis
06/20/2002US20020076410 Administrating antigens for passive immunization against pathogens in dairy cows (and other milk producing mammals)
06/20/2002DE10063173A1 Harnstoff- und Urethanderivate Urea and urethane
06/20/2002DE10063111A1 Replikationsassay zur Auffindung antiviraler Substanzen Replication assay for the detection of antiviral substances
06/20/2002DE10060810A1 Coniosetin und Derivate davon, Verfahren zur Herstellung und Verwendung derselben Coniosetin and derivatives thereof, methods of making and using the same
06/20/2002DE10060809A1 Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker Substituted anthranilic acids, their use as a medicament or diagnostic, and she containing drug, as well as a pharmaceutical combination preparation with a sodium / hydrogen exchange (NHE) blockers
06/20/2002CA2436830A1 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
06/20/2002CA2434915A1 Therapeutic agent comprising a b-subunit of a protein toxin
06/20/2002CA2432739A1 Oxazolidinone photoaffinity probes
06/20/2002CA2431858A1 Targeted enzymes comprising substrate recognition sites and target binding sites
06/20/2002CA2431716A1 Targeted enzyme prodrug therapy
06/20/2002CA2431406A1 Quinazolinone derivatives
06/20/2002CA2431044A1 Oral compositions and use thereof
06/20/2002CA2430899A1 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test
06/20/2002CA2430458A1 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
06/20/2002CA2430297A1 Interferon-alpha induced gene
06/20/2002CA2430151A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents
06/20/2002CA2429951A1 Antimicrobial quinolones
06/20/2002CA2429755A1 Treatment and prevention of ebv infection and ebv-associated disorders
06/20/2002CA2429352A1 Antiviral agents for treatment of flaviviridae infections
06/20/2002CA2428216A1 Secreted proteins
06/20/2002CA2427872A1 Antimicrobial 2-pyridones, their compositions and uses
06/20/2002CA2425513A1 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
06/20/2002CA2365494A1 Lawsonia intracellularis vaccine
06/19/2002EP1215497A1 Diagnostics for transmissible spongiform encephalopathy
1 ... 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 ... 1798